Evidence map›Paper›PMID 35802761›Full record

ReviewJournal of immunology (Baltimore, Md. : 1950)2021

Mucosal Immunity in Cystic Fibrosis.

Christine M Bojanowski, Shiping Lu, Jay K Kolls

Open access · bronzeAbstract readReview
In one paragraph

Review in Journal of immunology (Baltimore, Md. : 1950), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
1.6field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 20 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Review
  12. Article
  13. Frontiers in immunology · 2024
    Review
  14. Article
  15. An ALARMINg Type 2 Response in Cystic Fibrosis-The Key to Understanding ABPA?American journal of respiratory and critical care medicine · 2023
    Article
  16. Immune Response in Cystic Fibrosis: Interplay between the Host and Microbes.International journal of molecular sciences · 2023
    Article
  17. Article
  18. Potential of Lactoferrin in the Treatment of Lung Diseases.Pharmaceuticals (Basel, Switzerland) · 2023
    Review
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Christine M BojanowskiSection of Pulmonary Diseases, Critical Care, and Environmental Medicine, Department of Medicine, Tulane University School of Medicine, New Orleans, LA; cbojanowski@tulane.edu.
Shiping LuDepartment of Microbiology and Immunology, Tulane University School of Medicine, New Orleans, LA; and.
Jay K KollsCenter for Translational Research in Infection and Inflammation, Department of Medicine, Tulane University School of Medicine, New Orleans, LA.ORCID 0000-0001-5151-6304
Tulane University · US

Funding

Tracking & Evaluation CoreU54GM104940 · NIGMS · LSU PENNINGTON BIOMEDICAL RESEARCH CTR · PI Peter Todd Katzmarzyk · 2012 to 2026
$69.1M
Training in CD4 T-cell Lung ImmunityR35HL139930 · NHLBI · TULANE UNIVERSITY OF LOUISIANA · PI KOLLS, JAY K · 2018 to 2024
$6.3M
Development of Novel Adjuvants LTA and LTA1R01AI114697 · NIAID · TULANE UNIVERSITY OF LOUISIANA · PI NORTON, ELIZABETH B · 2015 to 2019
$2.1M
Immunotherapy of KPC InfectionR01AI149119 · NIAID · TULANE UNIVERSITY OF LOUISIANA · PI KOLLS, JAY K · 2020 to 2023
$1.9M
NHLBI NIH HHS R35 HL139930NIAID NIH HHS R01 AI114697NIAID NIH HHS R01 AI149119NIGMS NIH HHS U54 GM104940
6 · The paper itself

Abstract

The highly complex and variable genotype-phenotype relationships observed in cystic fibrosis (CF) have been an area of growing interest since the discovery of the CF transmembrane conductance regulator (

Indexed as

Cystic FibrosisCystic Fibrosis Transmembrane Conductance RegulatorHumansImmunity, MucosalInflammationLungPhenotypeCystic Fibrosis Transmembrane Conductance Regulator

Identifiers

PMID35802761
PMCPMC9270582
OpenAlexW4200478162

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.